ARRIVENT BIOPHARMA, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ARRIVENT BIOPHARMA, INC. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $85.23M, a 13.13% increase year-over-year.
- ARRIVENT BIOPHARMA, INC. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $54.73M, a 739.73% increase year-over-year.
- ARRIVENT BIOPHARMA, INC. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $86.09M.
- ARRIVENT BIOPHARMA, INC. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $75.34M.
- ARRIVENT BIOPHARMA, INC. stock issued during period, value, new issues for fiscal 2025 was $202.63M, a 10.60% increase from fiscal 2024.
- ARRIVENT BIOPHARMA, INC. stock issued during period, value, new issues for fiscal 2024 was $183.22M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $85.23M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $54.73M 10-Q · filed 2026-08-12 | |
| 2025-12-31 | $202.63M 10-K · filed 2026-03-05 | |
| 2025-09-30 | $86.09M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $75.34M 10-Q · filed 2026-08-12 | |
| 2025-03-31 | $6.52M 10-Q · filed 2026-08-12 | |
| 2024-12-31 | $183.22M 10-K · filed 2026-03-05 | |
| 2024-03-31 | $183.22M 10-Q · filed 2025-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |